Racial and ethnic underrepresentation in dermatology clinical trials.
clinical trials
diversity
ethnic representation
health equity
health justice
racial representation
representation
skin of color
Journal
Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
29
12
2022
revised:
03
04
2023
accepted:
07
04
2023
medline:
18
7
2023
pubmed:
17
4
2023
entrez:
16
4
2023
Statut:
ppublish
Résumé
Including participants of diverse racial and ethnic populations in clinical trials is important to reduce disparities and promote health care equity. To evaluate racial and ethnic representation in dermatology clinical trials. Participant data from dermatology trials completed in the United States from 2017 to 2021 from ClinicalTrials.gov were compared to census data to determine if minority groups were represented at rates that reflect population demographics. Participation was compared with prevalence rates for the most underrepresented racial group. Of 246 trials that met inclusion criteria, 87.4% (215) reported racial data. Compared to census data, Black/African American, American Indian/Alaskan Native, and 2 or more races were underrepresented. Hispanic or Latinos were an underrepresented ethnic group. The search was limited to ClinicalTrials.gov registered studies that fell within search parameters. Race reporting methods were not specified. Detailed analysis was only performed for the most underrepresented racial group. Certain minority groups were underrepresented in dermatology trials. Black/African Americans were most underrepresented and underrepresented even when accounting for prevalence rates. Trial representation that accurately reflects population demographics and subgroup prevalence rates can help reduce health inequity, improve clinical understanding, and enhance treatment access for the growing diverse population.
Sections du résumé
BACKGROUND
Including participants of diverse racial and ethnic populations in clinical trials is important to reduce disparities and promote health care equity.
OBJECTIVE
To evaluate racial and ethnic representation in dermatology clinical trials.
METHODS
Participant data from dermatology trials completed in the United States from 2017 to 2021 from ClinicalTrials.gov were compared to census data to determine if minority groups were represented at rates that reflect population demographics. Participation was compared with prevalence rates for the most underrepresented racial group.
RESULTS
Of 246 trials that met inclusion criteria, 87.4% (215) reported racial data. Compared to census data, Black/African American, American Indian/Alaskan Native, and 2 or more races were underrepresented. Hispanic or Latinos were an underrepresented ethnic group.
LIMITATIONS
The search was limited to ClinicalTrials.gov registered studies that fell within search parameters. Race reporting methods were not specified. Detailed analysis was only performed for the most underrepresented racial group.
CONCLUSION
Certain minority groups were underrepresented in dermatology trials. Black/African Americans were most underrepresented and underrepresented even when accounting for prevalence rates. Trial representation that accurately reflects population demographics and subgroup prevalence rates can help reduce health inequity, improve clinical understanding, and enhance treatment access for the growing diverse population.
Identifiants
pubmed: 37062462
pii: S0190-9622(23)00681-3
doi: 10.1016/j.jaad.2023.04.011
pii:
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
293-300Informations de copyright
Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Conflict of interest None disclosed.